Format
Sort by
Items per page

Send to

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 178

1.

Metabolite Identification, Reaction Phenotyping, and Retrospective Drug-Drug Interaction Predictions of 17-Deacetylnorgestimate, the Active Component of the Oral Contraceptive Norgestimate.

Ahire D, Sinha S, Brock B, Iyer R, Mandlekar S, Subramanian M.

Drug Metab Dispos. 2017 Jun;45(6):676-685. doi: 10.1124/dmd.116.073940. Epub 2017 Mar 10.

PMID:
28283499
2.

Nonoral combined hormonal contraceptives and thromboembolism: a systematic review.

Tepper NK, Dragoman MV, Gaffield ME, Curtis KM.

Contraception. 2017 Feb;95(2):130-139. doi: 10.1016/j.contraception.2016.10.005. Epub 2016 Oct 19. Review.

PMID:
27771476
3.

Simultaneous determination of estrogens (ethinylestradiol and norgestimate) concentrations in human and bovine serum albumin by use of fluorescence spectroscopy and multivariate regression analysis.

Hordge LN, McDaniel KL, Jones DD Jr, Fakayode SO.

Talanta. 2016 May 15;152:401-9. doi: 10.1016/j.talanta.2016.02.034. Epub 2016 Feb 17.

PMID:
26992536
4.

UPLC-MS/MS assay for the simultaneous determination of ethinyl estradiol, norgestimate and 17-Desacetyl norgestimate at low pg/mL in human plasma.

Huang MQ, Kang L, Wang W, Skee D, Chen M, Lin ZJ, Verhaeghe T, Weng N.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Apr 1;1017-1018:1-9. doi: 10.1016/j.jchromb.2016.01.054. Epub 2016 Feb 23.

PMID:
26930373
5.

Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome.

Adeniji AA, Essah PA, Nestler JE, Cheang KI.

J Womens Health (Larchmt). 2016 Jun;25(6):638-45. doi: 10.1089/jwh.2015.5418. Epub 2016 Feb 12.

6.

Hypercoagulability in adolescent girls on oral contraceptives-global coagulation profile and estrogen receptor polymorphisms.

Zia A, Callaghan MU, Callaghan JH, Sawni A, Bartlett H, Backos A, Marshall S, Chitlur M, Rajpurkar M.

Am J Hematol. 2015 Aug;90(8):725-31. doi: 10.1002/ajh.24064.

7.

Molecular action of norgestimate: new developments.

Paris F, Balaguer P, Rimbault F, Gaspari L, Sultan C.

Gynecol Endocrinol. 2015 Jun;31(6):487-90. doi: 10.3109/09513590.2015.1016904. Epub 2015 May 13.

PMID:
25970022
8.
9.

Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome.

Hagag P, Steinschneider M, Weiss M.

J Reprod Med. 2014 Sep-Oct;59(9-10):455-63.

PMID:
25330687
10.

A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial.

Jaisamrarn U, Chaovisitsaree S, Angsuwathana S, Nerapusee O.

Contraception. 2014 Nov;90(5):535-41. doi: 10.1016/j.contraception.2014.06.002. Epub 2014 Jun 12.

PMID:
25074072
11.

Mood and physical symptoms improve in women with severe cyclical changes by taking an oral contraceptive containing 250-mcg norgestimate and 35-mcg ethinyl estradiol.

Nyberg S.

Contraception. 2013 Jun;87(6):773-81. doi: 10.1016/j.contraception.2012.09.024. Epub 2012 Oct 31.

PMID:
23121822
12.

Types of combined oral contraceptives used by US women.

Hall KS, Trussell J.

Contraception. 2012 Dec;86(6):659-65. doi: 10.1016/j.contraception.2012.05.017. Epub 2012 Jul 6.

13.

Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.

Lidegaard O, Nielsen LH, Skovlund CW, Løkkegaard E.

BMJ. 2012 May 10;344:e2990. doi: 10.1136/bmj.e2990.

14.

Inhibition of diacylglycerol-sensitive TRPC channels by synthetic and natural steroids.

Miehe S, Crause P, Schmidt T, Löhn M, Kleemann HW, Licher T, Dittrich W, Rütten H, Strübing C.

PLoS One. 2012;7(4):e35393. doi: 10.1371/journal.pone.0035393. Epub 2012 Apr 17.

15.

Adolescents' experiences using the contraceptive patch versus pills.

Sucato GS, Land SR, Murray PJ, Cecchini R, Gold MA.

J Pediatr Adolesc Gynecol. 2011 Aug;24(4):197-203. doi: 10.1016/j.jpag.2011.02.001. Epub 2011 Mar 30.

PMID:
21454110
16.

The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.

Zhang J, Chung E, Yones C, Persson A, Mahnke L, Eley T, Xu X, Bertz R.

Antivir Ther. 2011;16(2):157-64. doi: 10.3851/IMP1724.

PMID:
21447864
17.

The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.

Sevinsky H, Eley T, Persson A, Garner D, Yones C, Nettles R, Krantz K, Bertz R, Zhang J.

Antivir Ther. 2011;16(2):149-56. doi: 10.3851/IMP1725.

PMID:
21447863
18.

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.

Anderson MS, Hanley WD, Moreau AR, Jin B, Bieberdorf FA, Kost JT, Wenning LA, Stone JA, Wagner JA, Iwamoto M.

Br J Clin Pharmacol. 2011 Apr;71(4):616-20. doi: 10.1111/j.1365-2125.2010.03885.x.

19.

Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.

Schwartz JI, Liu F, Wang YH, Pramanik B, Johnson-Levonas AO, Gutierrez MJ, Lai E, Wagner JA.

Am J Ther. 2009 Nov-Dec;16(6):487-95. doi: 10.1097/MJT.0b013e3181985130.

PMID:
19940609
20.

Association between efficacy and body weight or body mass index for two low-dose oral contraceptives.

Burkman RT, Fisher AC, Wan GJ, Barnowski CE, LaGuardia KD.

Contraception. 2009 Jun;79(6):424-7. doi: 10.1016/j.contraception.2008.12.013. Epub 2009 Mar 4.

PMID:
19442776

Supplemental Content

Support Center